Thinking about microdosing semaglutide? Here's what the evidence says

What the STEP 1 trial tells us, and what it deliberately doesn't test

The phrase "microdosing semaglutide" circulates widely online, often with the suggestion that a fraction of the licensed dose can deliver most of the benefit with fewer side effects. The best available evidence points in a more complicated direction. The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with obesity or overweight and at least one weight-related condition. Participants followed a defined titration plan: 0.25 mg weekly for the first month, doubling each month until reaching 2.4 mg, the maintenance dose. Over 68 weeks, that group lost roughly 15% of body weight on average. That figure is cited everywhere, and it applies specifically to people who completed the full titration, at licensed doses, in a structured programme.

What STEP 1 was not designed to test is whether a persistent sub-therapeutic dose (say, 0.25 mg or 0.5 mg held indefinitely) produces comparable or even partial results. No large randomised trial has answered that question, because the licensed development programme was built around reaching the 2.4 mg maintenance dose. The 0.25 mg starting dose exists to ease the body in, not to treat. Using it as a fixed long-term dose is a different intervention entirely, and one without a published evidence base for weight management.

That gap in the evidence is worth sitting with. If you are curious whether Wegovy can be microdosed, the honest answer is that absence of trial data does not mean microdosing is definitively useless; it means nobody yet knows, and that uncertainty is exactly why prescribers are cautious about it.

Why side effects drive the microdosing conversation, and what prescribers actually do about them

A question our prescribers hear most weeks is some version of: "Can I just stay on a lower dose until the nausea settles?" It is a completely reasonable instinct. The most common side effects of semaglutide are gastrointestinal (nausea, loose stools, indigestion, and sometimes vomiting) and they tend to peak in the days after a dose increase. The licensed titration schedule is already designed to minimise this: four weeks at each step before moving up, giving the gut time to adapt. For many people, this structured slow approach is enough. The NHS medicines guidance on semaglutide describes these effects as typically mild to moderate and often settling within days to a couple of weeks.

Where side effects are genuinely persistent or disruptive, the prescribing response within the licensed framework is to delay the next dose increase, or in some cases to hold the current dose for longer than the standard four weeks. This is different from reducing the dose to a quantity the pen was not designed to measure. Pre-filled Wegovy pens deliver a fixed amount; they are not designed or calibrated for partial use. Self-adjusting by using a fraction of a pen introduces dosing uncertainty that a prescriber cannot verify or supervise.

The short answer: if side effects are the reason you are thinking about microdosing, the right route is telling your prescriber. The licensed schedule already has flexibility built into it. Using that flexibility properly, with clinical oversight, is not the same thing as improvising your own lower dose outside the protocol.

Microdosing, GLP-1 compounders and the UK regulatory position

Much of the microdosing conversation originates in the United States, where compounding pharmacies have supplied semaglutide at custom doses during periods of shortage. That practice does not translate directly to the UK. The MHRA regulates medicines here, and semaglutide for weight management is available as the branded Wegovy product through the licensed supply chain. Compounded or repackaged versions of semaglutide are not licensed in the UK for weight management, and the MHRA has warned repeatedly about unlicensed versions of GLP-1 medicines being sold online. Buying semaglutide without a valid prescription, from a seller who is not registered with the GPhC, to self-administer at an arbitrary dose carries real clinical risk alongside the legal and safety concerns.

If you are weighing up what a legitimate private prescription for Wegovy looks like (including how cost and dose interact) the guide to where to get Wegovy in the UK covers the regulatory landscape clearly. And if you are specifically curious about what the available evidence says on the benefits side of this question, the overview of proposed microdosing benefits maps that out honestly, including where the data runs thin.

The bottom line for anyone in the UK who wants semaglutide: the licensed route exists, it works, and if tolerability is the worry, that is a conversation worth having with a prescriber before adjusting anything yourself.

What the licensed route looks like, and where a consultation fits in

If you want semaglutide for weight management, Wegovy is the licensed product in the UK. Adults with a BMI of 30 or above, or 27 or above alongside a qualifying weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol, may be suitable. Lower BMI thresholds apply for some ethnic backgrounds under NICE guidance. A prescriber reviews the full clinical picture (other medicines, relevant health history, realistic goals) before deciding whether treatment is appropriate and at what starting point.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber, not processed by an automated system. The free consultation is the starting point; if treatment is clinically suitable, it is approved the same day. The dose schedule your prescriber sets is based on the evidence and on you, it is not a negotiation, but it is a conversation. If side effects arise or titration feels fast, that conversation continues through aftercare. That, practically speaking, is what supervised treatment means.

You can read more about the clinical evidence behind semaglutide's effectiveness if you want the fuller picture before deciding. Or take a look at our weight management treatment overview to see how Wegovy sits alongside other licensed options. If you have got questions before starting, our FAQs cover the ones people ask most. When you are ready, speak to our prescribers through the free consultation, it costs nothing, and it is the only way to know whether semaglutide is the right fit for you.